Active substance
Results for the substance mirikizumab
4 results
About this active substance
Mirikizumab is a monoclonal antibody used for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. It works by blocking interleukin-23 (IL-23), a protein involved in chronic inflammation, thereby reducing symptoms and promoting remission.
The medication is administered via subcutaneous injection or intravenous infusion, according to a specific regimen. It is effective in reducing inflammation and improving patients' quality of life.
Side effects may include upper respiratory tract infections, headache, fatigue, and injection site reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Mirikizumab. This medication must be administered under the supervision of a specialist.
The medication is administered via subcutaneous injection or intravenous infusion, according to a specific regimen. It is effective in reducing inflammation and improving patients' quality of life.
Side effects may include upper respiratory tract infections, headache, fatigue, and injection site reactions. Close monitoring is essential to manage potential complications.
Consult your doctor to discuss the benefits and risks of treatment with Mirikizumab. This medication must be administered under the supervision of a specialist.
-
-
OMVOH 300mg concentrate for solution for infusion ELI LILLY ORIGINAL MEDICINE
-
OMVOH 200mg solution for injection in pre-filled pen ELI LILLY ORIGINAL MEDICINE
-
OMVOH 100MG+200mg solution for injection in pre-filled pen ELI LILLY ORIGINAL MEDICINE